Cabaletta Bio, Inc. (CABA) Stock Score, Valuation & Financial Research

Cabaletta Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CABA

Cabaletta Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.92. These figures are a research snapshot, not a buy or sell recommendation.

What Cabaletta Bio, Inc. does

Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Cabaletta Bio is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model focuses on the research and development of proprietary cell therapies, specifically its CABA platform, to treat autoimmune diseases, relying on capital raises and financing activities to fund operations.

Products and services

  • The company is developing a portfolio of targeted cell therapies, including its lead candidate rese-cel, which utilizes Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) to potentially reset the immune system in patients with autoimmune conditions.

Brands and product families

  • CABA — Cabaletta Approach to B cell Ablation platform. Source
  • RESET — Clinical trial program brand for autoimmune disease therapies. Source

Customer types

Patients with autoimmune diseases.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Cellares — A partnership to utilize the Cellares manufacturing platform to support the company's RESET clinical trials. Source

Business strengths to evaluate

  • Proprietary CABA platform technology Source
  • Clinical pipeline targeting high-unmet-need autoimmune conditions Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CABA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.92
Market capitalization:
313.07M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -181.32M
Free cash flow:
USD -132.31M
Cash:
USD 225.1M
Total debt:
USD 25.71M
EPS:
USD -1.58

What stands out

  • Free cash flow is USD -132.31M, negative for the stored period.
  • The balance sheet shows USD 225.1M of cash versus USD 25.71M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 199.39M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CABA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CABA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CABA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CABA to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of CABA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CABA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.